Evidence-based management of thrombosis in the antiphospholipid antibody syndrome.
Recommendations for the management of thrombosis in the antiphospholipid antibody syndrome have been based largely on retrospective case series. Several clinical trials have been recently published on the management of thrombosis in general. Two clinical trials have specifically addressed thrombosis in antiphospholipid antibody syndrome, and one is underway. These new clinical trials have challenged the previous dogma of a target International Normalized Ratio of 3 to 4 ("high-intensity" warfarin).
Petri
Michelle
M
Department of Medicine: Rheumatology, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA. mpetri@welch.jhu.edu
D000925:Anticoagulants / Q000008:administration & dosage; D016736:Antiphospholipid Syndrome / Q000150:complications*; D001241:Aspirin / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D019934:International Normalized Ratio; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D013927:Thrombosis / Q000150:complications / Q000517:prevention & control* / Q000628:therapy; D014859:Warfarin / Q000008:administration & dosage
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D001241:Aspirin